Fentanyl Citrate Recall: Urgent Medical Alert – Morning
- As of September 1, 2025, a nationwide recall has been initiated for all lots of Fentanyl Citrate for Injection, manufactured by Teva pharmaceuticals.
- The United States Food and Drug Administration (FDA) announced the recall after Teva identified the presence of particulate matter in some vials during routine testing.
- The recall encompasses all lots of Fentanyl Citrate for Injection, across all strengths.
Fentanyl Citrate Recall: what patients and Healthcare Providers Need to Know
Table of Contents
As of September 1, 2025, a nationwide recall has been initiated for all lots of Fentanyl Citrate for Injection, manufactured by Teva pharmaceuticals. This action, prompted by concerns over potential particulate matter discovered in vials, underscores the critical importance of vigilant quality control in pharmaceutical production and patient safety.
The Issue: Particulate Matter and Potential Risks
The United States Food and Drug Administration (FDA) announced the recall after Teva identified the presence of particulate matter in some vials during routine testing. While the exact nature of the particles is still under inquiry, the presence of foreign substances in injectable medications carries inherent risks. These risks can range from localized inflammation and irritation to more severe complications like blockages in blood vessels,possibly leading to organ damage or even death.
Which Products Are Affected?
The recall encompasses all lots of Fentanyl Citrate for Injection, across all strengths. This medication is commonly used in anesthesia, pain management, and as a component of regional anesthesia during surgical procedures. specifically,the recall includes 10 mL vials containing 50 mcg/mL,2 mL vials containing 50 mcg/mL,and 1 mL vials containing 50 mcg/mL. A complete list of recalled lot numbers can be found on the FDA’s website and through Teva’s dedicated recall portal.
What Should Patients Do?
Patients currently receiving Fentanyl Citrate injections should not discontinue their medication without first consulting their healthcare provider. Abruptly stopping fentanyl can lead to serious withdrawal symptoms. Instead, patients should contact their doctor or pharmacist to discuss choice pain management options and to determine if their specific lot number is affected by the recall.
Guidance for Healthcare Providers
Healthcare professionals are advised to immediately quarantine all affected lots of Fentanyl Citrate for Injection. The FDA recommends contacting Teva Pharmaceuticals for instructions on returning the product.Providers should also review their records to identify patients who have received the recalled medication and proactively reach out to discuss potential monitoring or alternative treatment plans.
The FDA is working with Teva to ensure that the recall is effective and that patients are not exposed to potentially harmful products.
Reporting Adverse Events
Any adverse events potentially related to the use of recalled Fentanyl Citrate should be reported to the FDA’s MedWatch program. This reporting system allows the FDA to track and analyze safety signals, helping to prevent future harm. Reports can be submitted online through the MedWatch website or by phone at 1-800-FDA-1088.
Looking Ahead: Ensuring Medication Safety
This recall serves as a crucial reminder of the complex systems in place to safeguard the pharmaceutical supply chain.Ongoing vigilance from manufacturers, healthcare providers, and regulatory agencies like the FDA is essential to maintaining the integrity of medications and protecting patient health. The FDA continues to investigate the source of the particulate matter and will provide updates as more facts becomes available.